These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1270 related items for PubMed ID: 11491207

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [Abstract] [Full Text] [Related]

  • 3. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [Abstract] [Full Text] [Related]

  • 4. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
    Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL.
    Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 Study Group.
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [Abstract] [Full Text] [Related]

  • 6. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL.
    Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
    [Abstract] [Full Text] [Related]

  • 7. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
    Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH.
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
    [Abstract] [Full Text] [Related]

  • 8. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [Abstract] [Full Text] [Related]

  • 9. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [Abstract] [Full Text] [Related]

  • 10. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 11. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R, Xu Y, Abbadessa M, Quartet Study Group.
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
    [Abstract] [Full Text] [Related]

  • 12. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [Abstract] [Full Text] [Related]

  • 13. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet [corrected] Study Group.
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E, Ramirez G, Defronzo R.
    Arch Intern Med; 2004 Oct 25; 164(19):2097-104. PubMed ID: 15505122
    [Abstract] [Full Text] [Related]

  • 20. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
    Patel J, Anderson RJ, Rappaport EB.
    Diabetes Obes Metab; 1999 May 25; 1(3):165-72. PubMed ID: 11220295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.